Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the.

Similar presentations


Presentation on theme: "Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the."— Presentation transcript:

1 Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the Diabetic Ulcer Study Group *  Journal of Vascular Surgery  Volume 21, Issue 1, Pages (January 1995) DOI: /S (95) Copyright © 1995 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

2 Fig. 1 Percentage of patients with complete wound closure. Cummulative summary of percentage of patients achieving complete wound closure during 20-week study period. Journal of Vascular Surgery  , 71-81DOI: ( /S (95) ) Copyright © 1995 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

3 Fig. 2 Median reduction in wound area of target ulcer during course of study. Observations are carried forward for patients who did not complete 20 weeks of treatment or missed visits. Journal of Vascular Surgery  , 71-81DOI: ( /S (95) ) Copyright © 1995 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions


Download ppt "Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the."

Similar presentations


Ads by Google